Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2012-08-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Australian Trial in Acute Hepatitis C
NCT00192569
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
NCT02065999
Control and Elimination Within Australia of Hepatitis C From People Living With HIV
NCT02102451
Qualification of Point-of-Care Assays for Management of HCV Patients
NCT02335320
Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)
NCT05016609
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To evaluate the effect of successful prior treatment or spontaneous clearance of recently acquired HCV infection on long-term quality of life, social functioning, injecting behaviour, mental health and liver health.
2. To assess the incidence of HCV re-infection following prior treatment induced clearance or spontaneous clearance of recently acquired chronic HCV infection.
3. To determine predictors of HCV re-infection following recently acquired HCV infection treatment.
4. To determine frequency and predictors of new mixed and superinfections in ATAHC subjects with persistent viraemia.
5. To add to a tissue repository of serum and PBMCs from well-characterised patients treated for recently acquired HCV infection to allow future examination of the role of other variables that may potentially impact on the prognosis and outcomes of early HCV treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provision of written, informed consent.
Exclusion Criteria
* Inability or unwillingness to comply with study collection requirements.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of New South Wales
OTHER
Kirby Institute
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gail Matthews, MBChB, MRCP (UK), FRACP, PhD
Role: PRINCIPAL_INVESTIGATOR
University of New South Wales, Syndey Australia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Vincent's Hospital
Sydney, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
UNSW Kirby Institute for infection and immunity in society Homepage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VHCRP1105
Identifier Type: OTHER
Identifier Source: secondary_id
VHCRP1105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.